REIMAGINE YOUR LIFE WITH HAE

Reimagine your life with fewer attacks

Fewer attacks or zero attacks for period of time in the clinical studies

People taking TAKHZYRO in 2 clinical studies, a 6.5-month
study and a 2.5-year, open-label extension study, had HAE
attacks less often. Some people in the studies had
zero attacks. Want to see the details?

In a 6.5-month clinical study of 125 people with HAE 12 years of age and older, TAKHZYRO significantly reduced the number of monthly attacks, compared with placebo. People taking TAKHZYRO also had fewer moderate or severe attacks and fewer attacks requiring acute treatment, compared with placebo. And according to a supportive analysis, there were people taking TAKHZYRO who had zero attacks during the entire clinical trial. In the 2.5-year, long-term, open-label extension study with 212 people with HAE, people taking TAKHZYRO had similar results compared with baseline. Baseline means a person's attack rate before beginning treatment in either the 6.5-month clinical trial or the long-term, open-label study. Long term safety of TAKHZYRO was the primary endpoint in the open-label extension study.

More Study Info

SELECT IMPORTANT SAFETY INFORMATION

TAKHZYRO may cause serious side effects, including allergic reactions.